Addex Therapeutics Ltd (ADXN) Financial Analysis & Valuation | Quarter Chart
Addex Therapeutics Ltd (ADXN)
ADXNPrice: $6.88
Fair Value: 🔒
🔒score
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-prot... more
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and comm... more
Description
Shares
| Market Cap | $4.54M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CH | CEO | Timothy Mark Dyer |
| IPO Date | 2020-02-12 | CAGR | -0.13% |
| Employees | 2 | Website | www.addextherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 689.53% | Total Yield | 689.53% |
ADXN chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.14M | P/E Ratio | -0.74 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 0.04 | P/B Ratio | 0.02 |
| P/CF Ratio | -0.02 | P/FCF Ratio | -0.02 |
| EPS | $-9.25 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -80.42% | Gross Margin | -1.75% |
| Operating Margin | -18.39% | Profit Margin | -46.21% |
| ROE | -0.67% | ROA | -0.71% |
| ROCE | -0.33% | Current Ratio | 2.31 |
| Quick Ratio | 2.31 | Cash Ratio | 2 |
| Debt/Equity | 0.01 | Interest Coverage | -697.88 |
| Altman Z Score | -58.06 | Piotroski Score | 2 |